CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.77B, above the global median of $1.18B
- PositionOperating margin is 41.2%, higher than 95% of its Biotechnology peers (median -24.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.77BUSDvs all stocks (USD)
Revenue (TTM)
85.72MUSDvs all stocks (USD)
Profit Margin
-183.98%vs Biotechnology peers
Beta
1.02xvs all stocks
52-Week Change
113.50%vs all stocks
Market Capitalization
2.77BUSDvs all stocks (USD)
Enterprise Value
2.83BUSDvs all stocks (USD)
Forward P/E
-35.23xvs Biotechnology peers
Price to Sales (TTM)
32.23xvs Biotechnology peers
Price to Book (MRQ)
63.52xvs Biotechnology peers
Enterprise to Revenue
33.07xvs Biotechnology peers
Enterprise to EBITDA
-80.17xvs Biotechnology peers
Gross Margin
94.90%vs Biotechnology peers
Profit Margin
-183.98%vs Biotechnology peers
Operating Margin
41.18%vs Biotechnology peers
Return on Assets (TTM)
-18.14%vs Biotechnology peers
Return on Equity (TTM)
-837.07%vs Biotechnology peers
Revenue (TTM)
85.72MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2500USDUpdated Sep 28, 2026Quarterly Revenue Growth
6322.70%vs Biotechnology peers
Gross Profit (TTM)
45.44MUSDvs all stocks (USD)
EBITDA (TTM)
-35.36MUSDvs all stocks (USD)
Net Income (TTM)
-336.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
6322.66%vs Biotechnology peers
Operating Cash Flow (TTM)
-114.17MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-100.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
9.68MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
4.82MUSDFY2025 · Dec 31, 2025Gross Profit
4.86MUSDFY2025 · Dec 31, 2025Operating Income
-106.60MUSDvs all stocks (USD)
Pre-tax Income
-250.64MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.00KUSDFY2025 · Dec 31, 2025Net Income
-250.64MUSDFY2025 · Dec 31, 2025EBIT
-246.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-100.14MUSDFY2025 · Dec 31, 2025Research & Development
41.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
70.13MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.87MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.37USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.37USDFY2025 · Dec 31, 2025Basic Shares Outstanding
312.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
312.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-250.64MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-235.85MUSDFY2025 · Dec 31, 2025Free Cash Flow
-237.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
30.23MUSDFY2025 · Dec 31, 2025Income Tax Paid
3.00KUSDFY2025 · Dec 31, 2025Interest Paid
3.51MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-250.64MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.20MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
10.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
146.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
8.77MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-208.01MUSDFY2025 · Dec 31, 2025Sale of Investments
208.47MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.53MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
92.82MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-2.20MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.78MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
88.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
358.01MSharesUpdated Sep 28, 2026Float Shares
194.60MSharesUpdated Sep 28, 2026Shares Short
42.28MSharesUpdated Sep 28, 2026Short Ratio
10.36daysvs all stocks
Short % of Shares Outstanding
21.66%vs all stocks
% Held by Insiders
12.64%vs all stocks
% Held by Institutions
72.84%vs all stocks
Total Cash (MRQ)
38.21MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.1070USDUpdated Sep 28, 2026Total Debt (MRQ)
98.34MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.26xvs Biotechnology peers
Current Ratio (MRQ)
4.58xvs Biotechnology peers
Book Value per Share (MRQ)
0.1220USDUpdated Sep 28, 2026Total Assets
155.50MUSDvs all stocks (USD)
Total Current Assets
115.23MUSDFY2025 · Dec 31, 2025Total Liabilities
134.59MUSDFY2025 · Dec 31, 2025Total Non-current Assets
40.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
97.29MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
30.23MUSDFY2025 · Dec 31, 2025Other Short-term Investments
67.62MUSDFY2025 · Dec 31, 2025Accounts Receivable
3.92MUSDFY2025 · Dec 31, 2025Inventory
9.58MUSDFY2025 · Dec 31, 2025Accounts Payable
11.98MUSDFY2025 · Dec 31, 2025Short-term Debt
1.14MUSDFY2025 · Dec 31, 2025Deferred Revenue
517.00KUSDFY2025 · Dec 31, 2025Long-term Debt
97.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
134.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-2.34BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
20.91MUSDvs all stocks (USD)
52-Week Low
2.99USDUpdated Sep 28, 202652-Week High
8.27USDUpdated Sep 28, 202652-Week Change
113.50%vs all stocks
Beta
1.02xvs all stocks
50-Day MA
6.73USDUpdated Sep 28, 2026200-Day MA
4.89USDUpdated Sep 28, 2026Avg 10-Day Volume
5.81MSharesUpdated Sep 28, 2026Avg 30-Day Volume
4.87MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.07USDUpdated Sep 28, 2026Other Income / Expense
-143.39MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 41.2%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.41Industry median: -0.24Industry P95: 0.38Peers compared: 193
Return on equity is -837.1%, lower than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: -8.37Industry median: -0.24Industry P5: -1.76Peers compared: 193
Price-to-book is 63.52×, higher than 95% of its Biotechnology peers (median 4.62×)Significant
Price-to-book: 63.52Industry median: 4.62Industry P95: 31.44Peers compared: 193
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -1.84
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.77B, above the global median of $1.18BNotable
Market cap (USD): 2,774,773,164Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
HLB Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Rubicon Research Limited
Tier 1ProductionApproval-Gated PipelineRule
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Piramal Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Twist Bioscience Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Iovance Biotherapeutics, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC